The company had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms under the brand name BDFAVI, according to the statement.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2QUBwsW
via IFTTT
0 comments:
Post a Comment